Angiogenesis Inhibitors
Items 71 to 79 of 79 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SU 5402 | 215543-92-3 | sc-204308 sc-204308A | 1 mg 5 mg | $63.00 $98.00 | 36 | |
SU 5402 is a potent inhibitor of angiogenesis, primarily acting through the modulation of fibroblast growth factor receptor (FGFR) signaling pathways. By interfering with receptor activation, it disrupts the phosphorylation processes essential for endothelial cell proliferation and survival. This compound exhibits a unique ability to alter the dynamics of cellular interactions within the tumor microenvironment, influencing the balance of pro- and anti-angiogenic factors. Its selective action highlights its potential to finely tune vascular responses. | ||||||
(S)-(−)-Thalidomide | 841-67-8 | sc-208337 sc-208337A | 10 mg 50 mg | $203.00 $681.00 | ||
(S)-(-)-Thalidomide exhibits a distinctive mechanism in angiogenesis by targeting the tumor necrosis factor-alpha (TNF-α) pathway, which plays a crucial role in inflammatory responses. This compound modulates the expression of various cytokines, thereby influencing endothelial cell behavior and vascular permeability. Its ability to disrupt the formation of new blood vessels is linked to alterations in cell adhesion molecules and matrix metalloproteinases, ultimately reshaping the angiogenic landscape. | ||||||
BGJ398 | 872511-34-7 | sc-364430 sc-364430A sc-364430B sc-364430C | 5 mg 10 mg 50 mg 100 mg | $216.00 $252.00 $594.00 $1009.00 | 4 | |
BGJ398 is a selective inhibitor that disrupts angiogenesis by targeting the fibroblast growth factor receptor (FGFR) signaling pathway. This compound interferes with the downstream activation of key transcription factors involved in endothelial cell proliferation and migration. By modulating the interaction between FGFR and its ligands, BGJ398 alters the balance of pro-angiogenic and anti-angiogenic factors, effectively impeding the vascularization process. Its unique binding affinity enhances specificity in inhibiting aberrant angiogenic responses. | ||||||
GW788388 | 452342-67-5 | sc-363544 sc-363544A | 5 mg 25 mg | $95.00 $384.00 | ||
GW788388 is a potent inhibitor that selectively targets the vascular endothelial growth factor receptor (VEGFR) signaling pathway, crucial for angiogenesis. By binding to the receptor, it disrupts the phosphorylation cascade that activates downstream signaling molecules essential for endothelial cell survival and proliferation. This compound's unique interaction profile alters the expression of angiogenic factors, effectively modulating the angiogenic response and influencing vascular development dynamics. | ||||||
Apilimod | 541550-19-0 | sc-480051 sc-480051A | 100 mg 1 g | $428.00 $2652.00 | 5 | |
Apilimod is a selective modulator of the immune response that influences angiogenesis through its interaction with specific intracellular signaling pathways. It primarily inhibits the activity of phosphoinositide 3-kinase (PI3K), which plays a pivotal role in cellular processes such as growth and survival. By disrupting this pathway, Apilimod alters the balance of pro- and anti-angiogenic factors, thereby impacting endothelial cell behavior and vascular remodeling. Its unique mechanism highlights the intricate relationship between immune modulation and vascular development. | ||||||
Voacangine | 510-22-5 | sc-506417 | 0.1 mg | $188.00 | ||
Voacangine is a complex alkaloid known for its role in modulating angiogenesis through specific receptor interactions. Its unique structure allows for selective binding to vascular endothelial growth factor receptors, influencing endothelial cell proliferation and migration. The compound's stereochemistry plays a crucial role in its biological activity, affecting the conformational dynamics that govern its interaction with target proteins. This specificity can lead to distinct signaling pathways, impacting vascular development and homeostasis. | ||||||
Delanzomib, free base | 847499-27-8 | sc-396774 sc-396774A | 5 mg 10 mg | $160.00 $300.00 | ||
Delanzomib, free base, is a potent inhibitor of angiogenesis, acting through the modulation of proteasome activity. By disrupting the degradation of pro-angiogenic factors, it alters the balance of signaling molecules that regulate endothelial cell proliferation and migration. This interference with the ubiquitin-proteasome pathway leads to the accumulation of specific proteins that can either promote or inhibit vascular formation, showcasing its role in the complex network of angiogenic regulation. | ||||||
Apilimod mesylate | 870087-36-8 | sc-506232 sc-506232A | 25 mg 100 mg | $104.00 $416.00 | ||
Apilimod mesylate is notable for its selective inhibition of specific kinases involved in angiogenesis, particularly through modulation of the PI3K/Akt signaling pathway. This compound exhibits unique interactions with lipid membranes, influencing cellular uptake and distribution. Its ability to disrupt the formation of new blood vessels is linked to its impact on endothelial cell proliferation and migration, showcasing distinct reaction kinetics that alter vascular dynamics. The compound's solubility profile enhances its bioavailability, facilitating targeted cellular interactions. | ||||||
Apilimod Hydrochloride | 541550-19-0 non-salt | sc-506259 sc-506259A | 25 mg 100 mg | $104.00 $416.00 | ||
Apilimod Hydrochloride is characterized by its ability to modulate angiogenic processes through the inhibition of key signaling pathways. It interacts with various cellular receptors, influencing the balance of pro- and anti-angiogenic factors. The compound's unique affinity for specific protein targets alters cellular signaling cascades, affecting endothelial cell behavior. Additionally, its physicochemical properties, such as solubility and stability, play a crucial role in its interaction with biological membranes, impacting its overall efficacy in vascular modulation. | ||||||